Equillium reports $40.9M cash; EQ101 Phase 2 topline due Q2; Ono itolizumab option decision 2H 2024

Equillium, Inc.

Cash $40.9M at Dec 31, 2023; runway into 2H 2025.
EQ101 Phase 2 alopecia areata enrollment complete; topline data Q2 2024.
FY2023 revenue $36.1M (Ono partnership); net loss $13.3M vs $62.4M prior year.
Ono option exercise for itolizumab expected 2H 2024; $33M exercise payment plus $101M milestones.
Phase 3 EQUATOR aGVHD interim review expected Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Equillium, Inc. reported the fourth quarter and full year 2023 results: revenue $9.2 million.

Period: the fourth quarter and full year 2023
Revenue: $9.2 million
Result: reported results

Exact text from the filing

Revenue for the fourth quarter of 2023 was $9.2 million

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Equillium, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-076471

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.